Psyence BioMed unit signs term sheet for exclusive US ibogaine license, supply deal with PsyLabs
Bitget2026/09/28 11:02- Psyence Biomedical’s Texas unit TIRC signed a binding term sheet for an exclusive U.S. license to PsyLabs’ pharmaceutical-grade ibogaine.
- Definitive agreement targeted by Nov. 30, 2026; term sheet lapses if no deal is signed by that date.
- Arrangement includes exclusive U.S. supply from PsyLabs, with TIRC as exclusive U.S. wholesaler and distributor.
- Economics include up to about USD 1.3 million in development and regulatory milestones for the first drug candidate.
- Also includes an annual exclusivity fee starting after first FDA approval, plus low single-digit royalties on net sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
